We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In observance of the Labor Day holiday, Drug Industry Daily will not be published Monday, Sept. 7. The next issue will be published Tuesday, Sept. 8. Read More
The FDA issued a warning letter to Acella Pharmaceuticals of Alpharetta, Ga., for releasing excessively potent lots of its thyroid tablet product. Read More
RedHill Biopharma has announced positive steps in two late-stage trials evaluating its Yeliva (opaganib) for severe COVID-19 patients and said it plans to file an Emergency Use Authorization (EUA) for the drug as early as the end of the year. Read More
California this week passed a bill that would allow the state to partner with generic drugmakers to manufacture its own generics, making it the first state to try this approach to lowering drug prices. Read More
President Trump announced that he would meet with pharma executives this week to discuss drug pricing and his controversial “favored nations” executive order — but PhRMA claimed it hasn’t heard of any such meeting. Read More
Centers for Disease Control and Prevention Director Robert Redfield has sent a letter to the governors of all 50 states urging them to be prepared for COVID-19 vaccine distribution by Nov. 1 — just two days ahead of the presidential election. Read More
The National Institutes of Health (NIH) on Wednesday said that there’s currently not enough data to say if convalescent plasma should be recommended or rejected as a COVID-19 treatment, doubling down on its previous advice to the FDA to delay Emergency Use Authorization (EUA) until more evidence is available. Read More
An analysis of seven international clinical trials published yesterday found that corticosteroids help reduce the risk of death in the most severe COVID-19 patients. Read More